Form 15-12G Y-mAbs Therapeutics,

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 15

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Number: 001-38650  

 

Y-MABS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

202 Carnegie Center, Suite 301

Princeton, New Jersey 08540

(646) 885-8505

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

 

Common Stock, par value $0.0001 per share

(Title of each class of securities covered by this Form)

 

None

(Title of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)	x
Rule 12g-4(a)(2)	¨
Rule 12h-3(b)(1)(i)	x
Rule 12h-3(b)(1)(ii)	¨
Rule 15d-6	¨
Rule 15d-22(b)	¨

 

Approximate number of holders of record as of the certification or notice date:  One

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Y-mAbs Therapeutics, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person. 

 

	Y-MABS THERAPEUTICS, INC.
September 26, 2025	By:	/s/ Vanessa Wolfeler
	Name: Vanessa Wolfeler
	Title: President

 

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Uptime Institute Partners with the Governorate of Nineveh to Advance Iraq’s Digital Infrastructure at the U.S.-Iraq Business Summit
• Vusion Announces Agreement to Acquire In-Store Media (ISM), Accelerating the Creation of a Platform for Digital In-Store Retail Media and Advertising
• Hofseth BioCare ASA: NEW PEER-REVIEWED CLINICAL STUDY ON PROGO® PUBLISHED IN BIOMEDICINES DEMONSTRATES GLP-1 BENEFITS AND AN INCREASE LEAN MUSCLE MASS